Exendin-4–encapsulated dissolving microneedle arrays for efficient treatment of type 2 diabetes

Dissolving microneedles (DMNs) are microscopic needles capable of delivering encapsulated compounds and releasing them into the skin in a minimally invasive manner. Most studies indicate that encapsulating therapeutics in DMNs is an efficacious approach; however, the importance of evaluating the activity of encapsulated compounds, during the fabrication process, has not been examined in detail. Conducting an analysis of thermal, chemical, and physical stress factors, including temperature, pH, and the interaction of the polymer and therapeutics mixture during preparation, is essential for retaining the activity of encapsulated therapeutics during and after fabrication. Here, we optimised the thermal, chemical, and physical parameters for the fabrication of exendin-4 (Ex-4)–encapsulated DMNs (Ex-4 DMNs). Ex-4, a peptide agonist of glucagon-like peptide (GLP) receptor, is used for glycaemic control in patients with type 2 diabetes. Our findings indicate that optimising the parameters involved in DMN fabrication retained the activity of Ex-4 by up to 98.3 ± 1.5%. Ex-4 DMNs reduced the blood-glucose level in diabetic mice with efficiency similar to that of a subcutaneous injection. We believe that this study paves way for the commercialisation of an efficient and minimally invasive treatment for patients with type 2 diabetes.

[1]  Andrew C. Miklos,et al.  Protein crowding tunes protein stability. , 2011, Journal of the American Chemical Society.

[2]  Sang-Nae Cho,et al.  Centrifugal Lithography: Self‐Shaping of Polymer Microstructures Encapsulating Biopharmaceutics by Centrifuging Polymer Drops , 2017, Advanced healthcare materials.

[3]  M. Trautmann,et al.  Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. , 2011, Diabetes technology & therapeutics.

[4]  Yong Zhu,et al.  Hypoxia and H2O2 Dual-Sensitive Vesicles for Enhanced Glucose-Responsive Insulin Delivery. , 2017, Nano letters.

[5]  O. Yerlikaya,et al.  Importance of Dairy Products in Cardiovascular Diseases and Type 2 Diabetes , 2013, Critical reviews in food science and nutrition.

[6]  K. Nitta,et al.  Effect of ethanol on folding of hen egg‐white lysozyme under acidic condition , 2006, Proteins.

[7]  Kun-Ju Lin,et al.  The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo. , 2011, Biomaterials.

[8]  V. Meidan,et al.  Validation of a Static Franz Diffusion Cell System for In Vitro Permeation Studies , 2010, AAPS PharmSciTech.

[9]  Dennis D. Kim,et al.  Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. , 2003, The Journal of clinical endocrinology and metabolism.

[10]  Daniel E. Otzen,et al.  Protein drug stability: a formulation challenge , 2005, Nature Reviews Drug Discovery.

[11]  Keizo Fukushima,et al.  Two-layered dissolving microneedles formulated with intermediate-acting insulin. , 2012, International journal of pharmaceutics.

[12]  Shayan F Lahiji,et al.  Enhanced Transdermal Delivery by Combined Application of Dissolving Microneedle Patch on Serum-Treated Skin. , 2017, Molecular pharmaceutics.

[13]  Zhen Gu,et al.  Bioresponsive transcutaneous patches. , 2017, Current opinion in biotechnology.

[14]  M. Mahoney,et al.  Strategies for smoking cessation: what is new and what works? , 2008, Expert review of respiratory medicine.

[15]  E. Vega,et al.  Effect of polymer viscosity on physicochemical properties and ocular tolerance of FB-loaded PLGA nanospheres. , 2009, Colloids and surfaces. B, Biointerfaces.

[16]  S. M. Setter,et al.  Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus. , 2006, Clinical therapeutics.

[17]  A. Bond.  Exenatide (Byetta) as a Novel Treatment Option for Type 2 Diabetes Mellitus , 2006, Proceedings.

[18]  V. Torchilin,et al.  Structure and design of polymeric surfactant-based drug delivery systems. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[19]  Qian Rong-l,et al.  A better comprehension of “Management of Hyperglycemia in Type 2 Diabetes:A Patient-Centered Approach—Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)” , 2013 .

[20]  J. Stockman,et al.  Dissolving polymer microneedle patches for influenza vaccination , 2012 .

[21]  Akira Yamamoto,et al.  Improvement of Transdermal Delivery of Exendin-4 Using Novel Tip-Loaded Microneedle Arrays Fabricated from Hyaluronic Acid. , 2016, Molecular pharmaceutics.

[22]  J. Leahy.  Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects With Type 2 Diabetes , 2008 .

[23]  P. S. Kim,et al.  Nature of the charged-group effect on the stability of the C-peptide helix. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Hansen Luan,et al.  Rapidly Dissolvable Microneedle Patches for Transdermal Delivery of Exenatide , 2014, Pharmaceutical Research.

[26]  D. E. Anderson,et al.  pH-induced denaturation of proteins: a single salt bridge contributes 3-5 kcal/mol to the free energy of folding of T4 lysozyme. , 1990, Biochemistry.

[27]  Jaime Uribarri,et al.  Glucose, Advanced Glycation End Products, and Diabetes Complications: What Is New and What Works , 2003 .

[28]  S. Inzucchi,et al.  Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364–1379 , 2013, Diabetes Care.

[29]  L. B. Knudsen,et al.  Structure-activity studies of glucagon-like peptide-1. , 1994, The Journal of biological chemistry.

[30]  H. Shan,et al.  Microneedle Patches as Drug and Vaccine Delivery Platform. , 2017, Current medicinal chemistry.

[31]  Mark R Prausnitz,et al.  Insertion of microneedles into skin: measurement and prediction of insertion force and needle fracture force. , 2004, Journal of biomechanics.

[32]  Yong-Hee Kim,et al.  Thermo-reversible injectable gel based on enzymatically-chopped low molecular weight methylcellulose for exenatide and FGF 21 delivery to treat types 1 and 2 diabetes. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[33]  D. Klonoff,et al.  Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. , 2008, Current medical research and opinion.

[34]  Hyungil Jung,et al.  A patchless dissolving microneedle delivery system enabling rapid and efficient transdermal drug delivery , 2015, Scientific Reports.

[35]  A. Toraman,et al.  Sharps Injury Prevention for Hospital Workers , 2011, International journal of occupational safety and ergonomics : JOSE.

[36]  A. Young,et al.  Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes , 2004, Regulatory Peptides.

[37]  Hyungil Jung,et al.  Anti‐obesity effect of a novel caffeine‐loaded dissolving microneedle patch in high‐fat diet‐induced obese C57BL/6J mice , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[38]  T. Greten,et al.  Induction of hepatitis C virus (HCV)‐specific T cells by needle stick injury in the absence of HCV‐viraemia , 2007, European journal of clinical investigation.

[39]  Mark R Prausnitz,et al.  Dissolving microneedle patch for transdermal delivery of human growth hormone. , 2011, Small.

[40]  S. Chae,et al.  Long acting hyaluronate--exendin 4 conjugate for the treatment of type 2 diabetes. , 2010, Biomaterials.